Lexology September 26, 2024
McDermott Will & Emery

On September 9, the US House of Representatives passed H.R. 8333, known as the BIOSECURE Act, targeting WuXi AppTec, BGI, MGI, Complete Genomics, WuXi Biologics and Chinese biotechnology companies more broadly.

Measures & Context

If signed into law, the BIOSECURE Act would prohibit entities that receive US federal funding from doing business with foreign biotechnology companies affiliated with the People’s Liberation Army, including the five Chinese biotechnology companies explicitly named in the bill. The bill also seeks to prevent the transfer of US persons’ genetic information to foreign adversaries.

The bill addresses concerns that foreign biotechnology companies, particularly Chinese companies, could use genetic data for surveillance or espionage.

The bill’s measures are part of a broader set of restrictive measures...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Pharma / Biotech, Regulations
National Health Expenditures In 2023: Faster Growth As Insurance Coverage And Utilization Increased
Startup SiteOne Secures $100M to Forge Ahead With Novel Non-Opioid Pain Meds
Health care package winners and losers
A New Weight Loss Drug With No Side Effects? Yes…So Far
The AI Advantage: Reimagining the Future of Drug Development

Share This Article